Liraglutide

被引：142

作者：

Drucker, Daniel J. ^{[1
]}

Dritselis, Argyris ^{[2
]}

Kirkpatrick, Peter

机构：

[1] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada

[2] IMS Hlth, London NW1 6JB, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 04期

关键词：

INCRETIN-BASED THERAPIES; GLUCAGON-LIKE PEPTIDE-1; OPEN-LABEL; TYPE-2; EXENATIDE; METFORMIN; COMBINATION; EFFICACY; PLACEBO; SAFETY;

D O I：

10.1038/nrd3148

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In January 2010, liraglutide (Victoza; Novo Nordisk) — an injectable glucagon-like peptide 1 receptor agonist — was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.

引用

页码：267 / 268

页数：2

共 17 条

[1] Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies [J].

Ban, Kiwon ;

Hui, Sonya ;

Drucker, Daniel J. ;

Husain, Mansoor .

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2009, 3 (04) :245-259

[2] One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial [J].

Bunck, Mathijs C. ;

Diamant, Michaela ;

Corner, Anja ;

Eliasson, Bjorn ;

Malloy, Jaret L. ;

Shaginian, Rimma M. ;

Deng, Wei ;

Kendall, David M. ;

Taskinen, Marja-Riitta ;

Smith, Ulf ;

Yki-Jarvinen, Hannele ;

Heine, Robert J. .

DIABETES CARE, 2009, 32 (05) :762-768

[3] Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].

Buse, John B. ;

Rosenstock, Julio ;

Sesti, Giorgio ;

Schmidt, Wolfgang E. ;

Montanya, Eduard ;

Brett, Jason H. ;

Zychma, Marcin ;

Blonde, Lawrence .

LANCET, 2009, 374 (9683) :39-47

[4] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study [J].

Drucker, Daniel J. ;

Buse, John B. ;

Taylor, Kristin ;

Kendall, David M. ;

Trautmann, Michael ;

Zhuang, Dangliang ;

Porter, Lisa .

LANCET, 2008, 372 (9645) :1240-1250

[5] Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits [J].

Drucker, Daniel J. ;

Sherman, Steven I. ;

Gorelick, Fred S. ;

Bergenstal, Richard M. ;

Sherwin, Robert S. ;

Buse, John B. .

DIABETES CARE, 2010, 33 (02) :428-433

[6] Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial [J].

Garber, Alan ;

Henry, Robert ;

Ratner, Robert ;

Garcia-Hernandez, Pedro A. ;

Rodriguez-Pattzi, Hiromi ;

Olvera-Alvarez, Israel ;

Hale, Paula M. ;

Zdravkovic, Milan ;

Bode, Bruce .

LANCET, 2009, 373 (9662) :473-481

[7]

*IMS HLTH, 2009, IMS MIDAS

[8] Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration [J].

Knudsen, LB ;

Nielsen, PF ;

Huusfeldt, PO ;

Johansen, NL ;

Madsen, K ;

Pedersen, FZ ;

Thogersen, H ;

Wilken, M ;

Agerso, H .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (09) :1664-1669

[9]

KNUDSEN LB, 2010, ENDOCRINOLOGY 0304, DOI DOI 10.1210/EN.2009-1272

[10] Incretin-based therapies for type 2 diabetes mellitus [J].

Lovshin, Julie A. ;

Drucker, Daniel J. .

NATURE REVIEWS ENDOCRINOLOGY, 2009, 5 (05) :262-269

← 1 2 →